These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

754 related articles for article (PubMed ID: 22806632)

  • 1. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction.
    van Heerebeek L; Hamdani N; Falcão-Pires I; Leite-Moreira AF; Begieneman MP; Bronzwaer JG; van der Velden J; Stienen GJ; Laarman GJ; Somsen A; Verheugt FW; Niessen HW; Paulus WJ
    Circulation; 2012 Aug; 126(7):830-9. PubMed ID: 22806632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
    Paulus WJ; Tschöpe C
    J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct myocardial effects of beta-blocker therapy in heart failure with normal and reduced left ventricular ejection fraction.
    Hamdani N; Paulus WJ; van Heerebeek L; Borbély A; Boontje NM; Zuidwijk MJ; Bronzwaer JG; Simonides WS; Niessen HW; Stienen GJ; van der Velden J
    Eur Heart J; 2009 Aug; 30(15):1863-72. PubMed ID: 19487234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction.
    Hamdani N; Bishu KG; von Frieling-Salewsky M; Redfield MM; Linke WA
    Cardiovasc Res; 2013 Mar; 97(3):464-71. PubMed ID: 23213108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction.
    Franssen C; Chen S; Unger A; Korkmaz HI; De Keulenaer GW; Tschöpe C; Leite-Moreira AF; Musters R; Niessen HW; Linke WA; Paulus WJ; Hamdani N
    JACC Heart Fail; 2016 Apr; 4(4):312-24. PubMed ID: 26682792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depressive symptoms are common and associated with adverse clinical outcomes in heart failure with reduced and preserved ejection fraction.
    Kato N; Kinugawa K; Shiga T; Hatano M; Takeda N; Imai Y; Watanabe M; Yao A; Hirata Y; Kazuma K; Nagai R
    J Cardiol; 2012 Jul; 60(1):23-30. PubMed ID: 22445598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction.
    Paulus WJ; Dal Canto E
    JACC Heart Fail; 2018 Jan; 6(1):1-7. PubMed ID: 29284577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND.
    Brouwers FP; de Boer RA; van der Harst P; Voors AA; Gansevoort RT; Bakker SJ; Hillege HL; van Veldhuisen DJ; van Gilst WH
    Eur Heart J; 2013 May; 34(19):1424-31. PubMed ID: 23470495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes.
    Mátyás C; Németh BT; Oláh A; Török M; Ruppert M; Kellermayer D; Barta BA; Szabó G; Kökény G; Horváth EM; Bódi B; Papp Z; Merkely B; Radovits T
    Eur J Heart Fail; 2017 Mar; 19(3):326-336. PubMed ID: 27995696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shunxin decoction improves diastolic function in rats with heart failure with preserved ejection fraction induced by abdominal aorta constriction through cyclic guanosine monophosphate-dependent protein kinase Signaling Pathway.
    Jiaying Z; Xiangxiang W; Xuefeng LI; Yang Y; Yinghuan D; Yanbin S; Ping X; Mengru Z; Junnan Z; Miao LI; Shuwen Z; Rui Z; Ying T; Hao T; Feifei T
    J Tradit Chin Med; 2022 Oct; 42(5):764-772. PubMed ID: 36083484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
    Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
    Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Causes and pathophysiology of heart failure with preserved ejection fraction.
    Kovács Á; Papp Z; Nagy L
    Heart Fail Clin; 2014 Jul; 10(3):389-98. PubMed ID: 24975903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiomyocyte stiffness in diastolic heart failure.
    Borbély A; van der Velden J; Papp Z; Bronzwaer JG; Edes I; Stienen GJ; Paulus WJ
    Circulation; 2005 Feb; 111(6):774-81. PubMed ID: 15699264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial.
    Maisel AS; Shah KS; Barnard D; Jaski B; Frivold G; Marais J; Azer M; Miyamoto MI; Lombardo D; Kelsay D; Iqbal N; Taub PR; Kupfer K; Lee E; Clopton P; Zile M; Greenberg B
    J Card Fail; 2016 Apr; 22(4):283-93. PubMed ID: 26433086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy.
    Schwartzenberg S; Redfield MM; From AM; Sorajja P; Nishimura RA; Borlaug BA
    J Am Coll Cardiol; 2012 Jan; 59(5):442-51. PubMed ID: 22281246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction.
    Mohammed SF; Hussain S; Mirzoyev SA; Edwards WD; Maleszewski JJ; Redfield MM
    Circulation; 2015 Feb; 131(6):550-9. PubMed ID: 25552356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of characteristics and outcomes of patients with heart failure preserved ejection fraction versus reduced left ventricular ejection fraction in an urban cohort.
    Quiroz R; Doros G; Shaw P; Liang CS; Gauthier DF; Sam F
    Am J Cardiol; 2014 Feb; 113(4):691-6. PubMed ID: 24484862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential impact of heart rate and blood pressure on outcome in patients with heart failure with reduced versus preserved left ventricular ejection fraction.
    Maeder MT; Kaye DM
    Int J Cardiol; 2012 Mar; 155(2):249-56. PubMed ID: 21035207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population.
    Cheng RK; Cox M; Neely ML; Heidenreich PA; Bhatt DL; Eapen ZJ; Hernandez AF; Butler J; Yancy CW; Fonarow GC
    Am Heart J; 2014 Nov; 168(5):721-30. PubMed ID: 25440801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation.
    Kolijn D; Pabel S; Tian Y; Lódi M; Herwig M; Carrizzo A; Zhazykbayeva S; Kovács Á; Fülöp GÁ; Falcão-Pires I; Reusch PH; Linthout SV; Papp Z; van Heerebeek L; Vecchione C; Maier LS; Ciccarelli M; Tschöpe C; Mügge A; Bagi Z; Sossalla S; Hamdani N
    Cardiovasc Res; 2021 Jan; 117(2):495-507. PubMed ID: 32396609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.